vs

Side-by-side financial comparison of MODIV INDUSTRIAL, INC. (MDV) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $11.1M, roughly 1.1× MODIV INDUSTRIAL, INC.). MODIV INDUSTRIAL, INC. runs the higher net margin — 11.0% vs -1398.3%, a 1409.3% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -5.6%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -3.8%).

MODIV INDUSTRIAL, INC. is a U.S.-based industrial real estate enterprise focused on acquiring, owning and operating high-quality industrial properties mainly located in key logistics and distribution hubs across North America. It serves tenants from sectors including e-commerce fulfillment, manufacturing and third-party logistics, addressing rising demand for modern supply chain infrastructure.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

MDV vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.1× larger
RNA
$12.5M
$11.1M
MDV
Growing faster (revenue YoY)
RNA
RNA
+439.6% gap
RNA
434.0%
-5.6%
MDV
Higher net margin
MDV
MDV
1409.3% more per $
MDV
11.0%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-3.8%
MDV

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
MDV
MDV
RNA
RNA
Revenue
$11.1M
$12.5M
Net Profit
$1.2M
$-174.4M
Gross Margin
Operating Margin
45.8%
-1513.5%
Net Margin
11.0%
-1398.3%
Revenue YoY
-5.6%
434.0%
Net Profit YoY
-22.0%
-117.0%
EPS (diluted)
$0.02
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDV
MDV
RNA
RNA
Q4 25
$11.1M
Q3 25
$11.7M
$12.5M
Q2 25
$11.8M
$3.8M
Q1 25
$11.8M
$1.6M
Q4 24
$11.7M
$3.0M
Q3 24
$11.7M
$2.3M
Q2 24
$11.4M
$2.0M
Q1 24
$12.0M
$3.5M
Net Profit
MDV
MDV
RNA
RNA
Q4 25
$1.2M
Q3 25
$1.0M
$-174.4M
Q2 25
$-2.0M
$-157.3M
Q1 25
$829.0K
$-115.8M
Q4 24
$1.6M
$-102.3M
Q3 24
$-587.0K
$-80.4M
Q2 24
$1.3M
$-70.8M
Q1 24
$3.7M
$-68.9M
Operating Margin
MDV
MDV
RNA
RNA
Q4 25
45.8%
Q3 25
41.4%
-1513.5%
Q2 25
9.8%
-4448.7%
Q1 25
40.2%
-8360.9%
Q4 24
45.4%
-4069.6%
Q3 24
42.0%
-4200.9%
Q2 24
44.6%
-4040.4%
Q1 24
55.6%
-2178.6%
Net Margin
MDV
MDV
RNA
RNA
Q4 25
11.0%
Q3 25
9.0%
-1398.3%
Q2 25
-17.1%
-4089.3%
Q1 25
7.0%
-7360.0%
Q4 24
13.3%
-3439.5%
Q3 24
-5.0%
-3441.7%
Q2 24
11.6%
-3461.8%
Q1 24
31.1%
-1943.4%
EPS (diluted)
MDV
MDV
RNA
RNA
Q4 25
$0.02
Q3 25
$0.00
$-1.27
Q2 25
$-0.32
$-1.21
Q1 25
$-0.01
$-0.90
Q4 24
$0.07
$-0.80
Q3 24
$-0.18
$-0.65
Q2 24
$0.03
$-0.65
Q1 24
$0.33
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDV
MDV
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$14.4M
$350.2M
Total DebtLower is stronger
$261.5M
Stockholders' EquityBook value
$162.7M
$1.9B
Total Assets
$476.5M
$2.1B
Debt / EquityLower = less leverage
1.61×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDV
MDV
RNA
RNA
Q4 25
$14.4M
Q3 25
$8.3M
$350.2M
Q2 25
$5.8M
$243.9M
Q1 25
$6.2M
$254.2M
Q4 24
$11.5M
$219.9M
Q3 24
$6.8M
$370.2M
Q2 24
$18.9M
$575.8M
Q1 24
$18.4M
$471.4M
Total Debt
MDV
MDV
RNA
RNA
Q4 25
$261.5M
Q3 25
$279.7M
Q2 25
$279.7M
Q1 25
$279.7M
Q4 24
$279.8M
Q3 24
$279.7M
Q2 24
$279.7M
Q1 24
$279.6M
Stockholders' Equity
MDV
MDV
RNA
RNA
Q4 25
$162.7M
Q3 25
$164.8M
$1.9B
Q2 25
$165.6M
$1.2B
Q1 25
$171.1M
$1.3B
Q4 24
$190.1M
$1.4B
Q3 24
$186.3M
$1.5B
Q2 24
$187.0M
$1.2B
Q1 24
$188.0M
$830.9M
Total Assets
MDV
MDV
RNA
RNA
Q4 25
$476.5M
Q3 25
$499.6M
$2.1B
Q2 25
$498.9M
$1.4B
Q1 25
$506.8M
$1.5B
Q4 24
$507.8M
$1.6B
Q3 24
$507.4M
$1.6B
Q2 24
$519.5M
$1.3B
Q1 24
$522.5M
$951.5M
Debt / Equity
MDV
MDV
RNA
RNA
Q4 25
1.61×
Q3 25
1.70×
Q2 25
1.69×
Q1 25
1.63×
Q4 24
1.47×
Q3 24
1.50×
Q2 24
1.50×
Q1 24
1.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDV
MDV
RNA
RNA
Operating Cash FlowLast quarter
$15.0M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
12.34×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDV
MDV
RNA
RNA
Q4 25
$15.0M
Q3 25
$4.1M
$-156.2M
Q2 25
$3.9M
$-199.7M
Q1 25
$3.0M
$-124.8M
Q4 24
$18.2M
$-99.9M
Q3 24
$5.1M
$-65.6M
Q2 24
$4.7M
$-65.0M
Q1 24
$3.0M
$-70.4M
Free Cash Flow
MDV
MDV
RNA
RNA
Q4 25
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
MDV
MDV
RNA
RNA
Q4 25
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
MDV
MDV
RNA
RNA
Q4 25
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
MDV
MDV
RNA
RNA
Q4 25
12.34×
Q3 25
3.95×
Q2 25
Q1 25
3.68×
Q4 24
11.72×
Q3 24
Q2 24
3.55×
Q1 24
0.80×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons